Genotypic Evaluation of Chronic Exudative Macular Degeneration Despite Monthly Anti-Vascular Endothelial Growth Factor (VEGF) Therapy

West Coast Retina Medical Group, Inc.1 site in 1 country40 target enrollmentApril 2011

ConditionsWet AMD

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Wet AMD
Sponsor: West Coast Retina Medical Group, Inc.
Enrollment: 40
Locations: 1
Primary Endpoint: Genetic analysis of patients with chronic wet age-related macular degeneration despite continuous anti-VEGF treatment
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To obtain a genotypic analysis of patients with chronic exudative age-related macular degeneration noted to have subretinal or intraretinal edema despite continuous monthly Anti-VEGF therapy.

Registry

clinicaltrials.gov

Start Date

April 2011

End Date

June 2019

Last Updated

7 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

West Coast Retina Medical Group, Inc.

Responsible Party

Principal Investigator

Arthur D. Fu, MD

Principal Investigator

West Coast Retina Medical Group, Inc.

Eligibility Criteria

Inclusion Criteria

•Ability to provide written informed consent for participation in this study
•Subjects diagnoses of neovascular AMD who are on a monthly anti-VEGF regimen (have had \>10 or more ranibizumab and/or bevacizumab injections within the last year) and who still have intra-retinal or subretinal fluid as confirmed by the Investigator

Exclusion Criteria

•Subjects with a Pigment Epithelial Detachment Exclusively
•Subjects with Serous Pigment Epithelial Detachments
•Subjects with history of the following:
•idiopathic polypoidal choroidal vasculopathy
•pathologic degenerative myopia
•central serous chorioretinopathy
•familial drusen
•adult onset foveal pattern dystrophy

Outcomes

Primary Outcomes

Genetic analysis of patients with chronic wet age-related macular degeneration despite continuous anti-VEGF treatment

Time Frame: This is a one time only blood draw.

Secondary Outcomes

To evaluate demographic and clinical characteristics in patients treated with anti-VEGF therapy who fail to respond completely.(This is a one time only blood draw and assessment of clinical characteristics.)